SecBot SecBot
Biotech Drug Report Generated Jul 9, 2026

zelebrudomide

NRIX·Nurix Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
Unlikely before 2028-2029 if successful. Still in Phase 1 with no pivotal trial design disclosed. The trial's final completion is estimated at May 2027.
Why 3/10
Zelebrudomide is a Phase 1 asset with no hard dated binary catalyst (PDUFA, pivotal readout) scheduled in the next ~12 months. The next data updates are likely at medical conferences (ASH etc.) but no firm date is set. The trial primary completion was moved to May 2026 and final completion to May 2027. Moreover, the drug is no longer Nurix's lead asset, bexobrutideg (NX-5948) partnered with Roche dwarfs it in importance.
Actionable Insight NEUTRAL

Zelebrudomide is a secondary pipeline asset at Nurix. The stock's primary value driver is bexobrutideg (NX-5948) and its recently announced Roche partnership ($700M upfront). Watch for any Phase 1 data updates from zelebrudomide at hematology conferences (ASH/EHA), but this single drug alone will not meaningfully move the stock given the company's $1.24B pro-forma cash position and broader pipeline focus.

Price Chart

Loading chart...

Executive Summary

Zelebrudomide (NX-2127) is a first-in-class oral BTK/Ikaros/Aiolos dual degrader in Phase 1 testing for relapsed/refractory B-cell malignancies. Early data showed a 40.7% overall response rate in CLL. However, the program suffered a ~5-month partial clinical hold in 2023-2024 for manufacturing changes. More importantly, zelebrudomide is no longer Nurix's lead BTK degrader, the company's strategic focus has shifted to bexobrutideg (NX-5948), which just landed a massive $700M-upfront partnership with Roche worth up to $2.3B. Zelebrudomide remains in the pipeline but its contribution to NRIX's stock value is minimal at this stage.

How It Works

Zelebrudomide is an oral pill designed to destroy two types of proteins inside cancer cells: BTK (a protein that B-cell cancers rely on to grow) and Ikaros/Aiolos (proteins that suppress the immune system's ability to fight cancer). By degrading both simultaneously, it aims to kill cancer cells directly while also activating the immune system against them. This is a "targeted protein degrader", unlike traditional inhibitors that merely block a protein's activity, degraders destroy the protein entirely.

Trial Status

Zelebrudomide is in a first-in-human Phase 1a/1b trial (NCT04830137) for relapsed/refractory B-cell malignancies. The trial was placed on partial clinical hold in November 2023 due to a manufacturing transition but the FDA lifted the hold in March 2024. Enrollment resumed with an optimized R-diastereomer formulation. The Phase 1a dose-escalation cohort is ongoing (up to 48 patients), followed by Phase 1b dose-optimization. Primary completion was moved from Dec 2025 to May 2026; final completion from Dec 2026 to May 2027.

The Two-Sided Case

▲ Bull Case4
First-in-class dual mechanism, zelebrudomide simultaneously degrades BTK (a validated cancer target) and Ikaros/Aiolos (immune-modulatory proteins), potentially offering a double-hit against B-cell malignancies that have stopped responding to conventional BTK inhibitors.
Early Phase 1 data showed a 40.7% ORR in heavily pretreated CLL patients, with 2 complete responses (ongoing at 9.2 and 11.8 months) in NHL patients, meaningful activity in a patient population that had progressed on prior BTK inhibitors.
The optimized R-diastereomer formulation (post-clinical-hold) may improve the drug's therapeutic index and efficacy profile.
Nurix has a strong cash position (~$1.24B pro-forma post-Roche deal) and an established targeted protein degradation platform, providing ample runway to develop zelebrudomide without near-term financing risk.
▼ Bear Case5
Zelebrudomide has been eclipsed by bexobrutideg (NX-5948) as Nurix's lead BTK degrader, the Roche partnership makes clear that bexobrutideg is the priority, and zelebrudomide may face resource reallocation or deprioritization.
The 5-month partial clinical hold (Nov 2023 - Mar 2024) for manufacturing issues delayed enrollment and raised questions about drug-product consistency; the program is restarting months behind schedule.
Still early Phase 1 with no registrational trial design or regulatory guidance, a very long path to commercialization, likely 2028+ if successful.
Highly competitive BTK degrader landscape: BeiGene's BGB-16673 is in Phase 2/3, and multiple approved BTK inhibitors (ibrutinib, acalabrutinib, pirtobrutinib) already dominate the market. Zelebrudomide needs to show clear differentiation to carve out a niche.
The company conducted a $250M stock offering at $10.21/share in October 2025, significantly diluting existing shareholders, 24.5M new shares were issued.

Upcoming Catalysts

  • Potential Phase 1 data updates at major hematology conferences (ASH in December, EHA in June), no specific presentation confirmed yet
  • Phase 1a dose-escalation completion and selection of recommended Phase 2 dose
  • Transition to Phase 1b dose-optimization cohorts in specific B-cell malignancy subtypes

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 nurixtx.com3 ashpublications.org4 clinicaltrials.gov5 onlinelibrary.wiley.com6 ir.nurixtx.com7 ir.nurixtx.com8 markets.businessinsider.com9 sec.gov10 nurixtx.com11 veri.larvol.com